Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR Outcomes: Bempedoic Acid CV Outcomes in Statin Intolerant Patients
NCT02993406Phase 3Completed
- Sponsor
- Esperion Therapeutics
- Start
- Dec 2016
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial in cardiovascular diseases (CVD) and hypercholesterolemia comparing Bempedoic Acid with Placebo (2 arms). Primary endpoint: First Occurrence of Four Component Major Adverse Cardiovascular Events up to 68 months. Started Dec 2016; status: completed.
02
Drugs
bempedoic acid
03
Conditions
cardiovascular diseases (CVD)hypercholesterolemia
Beyond the preview
Go deeper on NCT02993406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993406.